Celldex Therapeutics, a biopharmaceutical company, has expanded its precision targeted immunotherapy platform by acquiring exclusive rights to FMS-like tyrosine kinase 3 ligand and CD40 ligand, from Amgen. Specific
Array BioPharma, a biopharmaceutical company, has dosed its first type 2 diabetic patient in a Phase I clinical trial with its novel small molecule glucokinase activator, ARRY-403. In
“Mel has served as President and Chief Executive Officer of three healthcare companies, as well as having extensive management experience in operations, finance, sales and international market development
Tolera Therapeutics, a biotechnology company, has received orphan drug status from the FDA for its initial lead candidate, TOL101, for prophylaxis of acute rejection of solid organ transplantation.
Phadia, an in vitro allergy diagnostics company, has received the FDA clearance for its ImmunoCAP Rapid, the first point-of-care test to assist in the diagnosis of allergy in
Netherlands-based biopharmaceutical company Kiadis Pharma has reported promising preliminary clinical data on Atir showing its potential in mismatched bone marrow transplantations. The clinical results from 19 end stage
Alimera Sciences, a biopharmaceutical company engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals, has reported that an independent Data Safety Monitoring Board has recommended the
Denmark-based pharmaceutical company H Lundbeck has reported that the Psychopharmacology Drug Advisory Committee appointed by the FDA voted unanimously that Serdolect is efficacious in the treatment of patients
Germany-based biopharmaceutical company Paion and Ergomed Clinical Research, a clinical development company, have reported encouraging data from the open-label Phase IIa study with the N-methyl-D-aspartic acid receptor antagonist
Medifocus, a Canada-based capital pool company, has reported positive clinical results from Phase II breast cancer treatment study that demonstrate significant efficacy when using the company’s proprietary focused
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.